Fundamental Analysis of Neurocrine Biosciences Inc - Growth / Value Index
NBIX - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.053
Tremendous increasing in Book Value last 3 year
Price to Book Ratio of 7.60 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 37.29 | 71.60 | -17.39 % | |
| Price to Book | 7.23 | 6.13 | -21.86 % | 5.88 |
| Price to Sales | 6.95 | 7.67 | -14.78 % | |
| Enterprise Value to EBITDA Multiple | 28.09 | 63.06 | 4.79 % |
NBIX - Profitability Highlights
Profitability Analysis
Company Earning excess return
All key Trailing Twelve Months Margin growing by 15 %
Piotroski F Score - Stable Value of 5.0
Good Return on Equity of 18.20% is achieved by the company
Good Net Margin of 18.65% is achieved by the company
Low Earning Yield of 2.55 %
EPS decline for last four quarters
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 18.20 | 8.56 | -5.41 % | 1.82 |
| Return On Asset | 13.57 | 5.87 | -9.94 % | 1.25 |
| Net Profit Margin | 18.65 | 10.71 | 3.17 % | 8.42 |
| Operating Profit Margin | 23.73 | 19.50 | 16.60 % | 20.43 |
| EBITDA Margin | 24.33 | 12.09 | -18.59 % | 21.64 |
Highlights
| Market Cap | 13627.26 M |
| Enterprise Value | 13546.26 M |
| Price/Book TTM | 7.23 |
| Outstanding Share | 100637 K |
| Float/ Outstanding Share | 98.78% |
| Dividend Yield | 1.11 % |
Share Holding
Guru Numbers
| Price/Graham No | 3.19 |
| Peter Lynch Ratio | 0.565 |
| Piotroski F Score | 5.00 |
| Altman Z Score | 9.05 |
| Sloan Ratio | -0.067 |
| Peter Lynch Fair Value | 90.79 |
NBIX - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 1982.00 M | 19.83 % | 0.0194 % |
| Gross Profit | 1938.00 M | 19.07 % | 0.829 % |
| EBITDA | 482300 K | 2.44 % | 28.53 % |
| Net Profit | 369700 K | 23.62 % | 70.62 % |
| EPS | 3.63 | 21.05 % | NA |
NBIX - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 89.06
Altman Z Score of 9.46 suggests good Stability
Debt to equity ratio has decreased and is lowest in last five years
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.076 | -23.17 % | 0.123 |
| Cash Ratio | 1.58 | -14.37 % | |
| Quick Ratio | 2.40 | -9.18 % | 2.47 |
| Shareholders Equity | 68.65 | -4.79 % | |
| Debt to EBITDA | 0.789 | 2.93 % |
Historical Valuation Ratios of Neurocrine Biosciences Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Neurocrine Biosciences Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Neurocrine Biosciences Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Neurocrine Biosciences Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)